Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1988 Dec 17;297(6663):1574–1578. doi: 10.1136/bmj.297.6663.1574

Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy.

P Kendall-Taylor 1, A L Crombie 1, A M Stephenson 1, M Hardwick 1, K Hall 1
PMCID: PMC1835292  PMID: 2906260

Abstract

Eleven euthyroid patients with severe Graves' eye disease were treated with intravenous methylprednisolone and followed up for six months or more by ophthalmological assessment, orbital computed tomography (CT), photographs, and antibody measurements. Papilloedema resolved in the single patient in whom it was present; visual acuity was abnormal in seven eyes initially and in only one eye after treatment; the intraocular pressure differential, which reflects muscle dysfunction, was initially abnormal in 18 eyes but showed a progressive and distinct improvement; nine patients showed substantial improvement in inflammatory signs. Exophthalmos improved early after treatment, but this improvement was not maintained. Orbital CT showed a pronounced reduction in the bulk of eye muscles after treatment in eight of nine patients. Autoantibodies to the thyroid stimulating hormone receptor declined. Adverse effects were trivial. Thus eight patients showed a clear response to intravenous methylprednisolone as judged by ophthalmic assessment and CT scan. The two patients who showed little response and one who had none all had a long history (more than a year) of ophthalmopathy. Results were better than those with oral steroids and adverse effects less. Treatment of Graves' eye disease is more likely to be effective if given early; patients should be referred promptly to specialist centres, where treatment with intravenous methylprednisolone should be considered.

Full text

PDF
1575

Images in this article

1577FIG 3
on p.1577

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartalena L., Marcocci C., Chiovato L., Laddaga M., Lepri G., Andreani D., Cavallacci G., Baschieri L., Pinchera A. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab. 1983 Jun;56(6):1139–1144. doi: 10.1210/jcem-56-6-1139. [DOI] [PubMed] [Google Scholar]
  2. Cole B. R., Brocklebank J. T., Kienstra R. A., Kissane J. M., Robson A. M. "Pulse" methylprednisolone therapy in the treatment of severe glomerulonephritis. J Pediatr. 1976 Feb;88(2):307–314. doi: 10.1016/s0022-3476(76)81009-8. [DOI] [PubMed] [Google Scholar]
  3. DAY R. M. Ocular manifestations of thyroid disease. Current concepts. Arch Ophthalmol. 1960 Sep;64:324–341. doi: 10.1001/archopht.1960.01840010326003. [DOI] [PubMed] [Google Scholar]
  4. Donaldson S. S., Bagshaw M. A., Kriss J. P. Supervoltage orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab. 1973 Aug;37(2):276–285. doi: 10.1210/jcem-37-2-276. [DOI] [PubMed] [Google Scholar]
  5. Gamblin G. T., Harper D. G., Galentine P., Buck D. R., Chernow B., Eil C. Prevalence of increased intraocular pressure in Graves' disease--evidence of frequent subclinical ophthalmopathy. N Engl J Med. 1983 Feb 24;308(8):420–424. doi: 10.1056/NEJM198302243080803. [DOI] [PubMed] [Google Scholar]
  6. Glinoer D., Etienne-Decerf J., Schrooyen M., Sand G., Hoyoux P., Mahieu P., Winand R. Beneficial effects of intensive plasma exchange followed by immunosuppressive therapy in severe Graves' ophthalmopathy. Acta Endocrinol (Copenh) 1986 Jan;111(1):30–38. doi: 10.1530/acta.0.1110030. [DOI] [PubMed] [Google Scholar]
  7. Jacobson D. H., Gorman C. A. Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment. Endocr Rev. 1984 Spring;5(2):200–220. doi: 10.1210/edrv-5-2-200. [DOI] [PubMed] [Google Scholar]
  8. Kelly W., Longson D., Smithard D., Fawcitt R., Wensley R., Noble J., Keeley J. An evaluation of plasma exchange for Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1983 May;18(5):485–493. doi: 10.1111/j.1365-2265.1983.tb02878.x. [DOI] [PubMed] [Google Scholar]
  9. Kendall-Taylor P., Atkinson S., Holcombe M. A specific IgG in Graves' ophthalmopathy and its relation to retro-orbital and thyroid autoimmunity. Br Med J (Clin Res Ed) 1984 Apr 21;288(6425):1183–1186. doi: 10.1136/bmj.288.6425.1183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kendall-Taylor P. The pathogenesis of Graves' ophthalmopathy. Clin Endocrinol Metab. 1985 May;14(2):331–349. doi: 10.1016/s0300-595x(85)80037-2. [DOI] [PubMed] [Google Scholar]
  11. Marcocci C., Bartalena L., Panicucci M., Marconcini C., Cartei F., Cavallacci G., Laddaga M., Campobasso G., Baschieri L., Pinchera A. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study. Clin Endocrinol (Oxf) 1987 Jul;27(1):33–42. doi: 10.1111/j.1365-2265.1987.tb00836.x. [DOI] [PubMed] [Google Scholar]
  12. McGregor A. M., Petersen M. M., McLachlan S. M., Rooke P., Smith B. R., Hall R. Carbimazole and the autoimmune response in Graves' disease. N Engl J Med. 1980 Aug 7;303(6):302–307. doi: 10.1056/NEJM198008073030603. [DOI] [PubMed] [Google Scholar]
  13. O'Neill W. M., Jr, Etheridge W. B., Bloomer H. A. High-dose corticosteroids: their use in treating idiopathic rapidly progressive glomerulonephritis. Arch Intern Med. 1979 May;139(5):514–518. doi: 10.1001/archinte.139.5.514. [DOI] [PubMed] [Google Scholar]
  14. Short C. D., Solomon L. R., Gokal R., Mallick N. P. Methylprednisolone in patients with membranous nephropathy and declining renal function. Q J Med. 1987 Nov;65(247):929–940. [PubMed] [Google Scholar]
  15. Taylor J. J., Young E. T., Holcombe M., Kendall-Taylor P. Evaluation of TBII activity in untreated Graves' disease using solubilised thyroid membranes. Ann Clin Biochem. 1985 Jul;22(Pt 4):366–370. doi: 10.1177/000456328502200406. [DOI] [PubMed] [Google Scholar]
  16. Teng C. S., Yeung R. T. Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study. J Clin Endocrinol Metab. 1980 Jan;50(1):144–147. doi: 10.1210/jcem-50-1-144. [DOI] [PubMed] [Google Scholar]
  17. Wang P. W., Hiromatsu Y., Laryea E., Wosu L., How J., Wall J. R. Immunologically mediated cytotoxicity against human eye muscle cells in Graves' ophthalmopathy. J Clin Endocrinol Metab. 1986 Aug;63(2):316–322. doi: 10.1210/jcem-63-2-316. [DOI] [PubMed] [Google Scholar]
  18. Weetman A. P., McGregor A. M., Ludgate M., Beck L., Mills P. V., Lazarus J. H., Hall R. Cyclosporin improves Graves' ophthalmopathy. Lancet. 1983 Aug 27;2(8348):486–489. doi: 10.1016/s0140-6736(83)90514-7. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES